Apyx Medical Corporation (APYX)
| Market Cap | 348.67M |
| Revenue (ttm) | 31.35M |
| Net Income (ttm) | -14.85M |
| Shares Out | 34.21M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $10.15 |
| Previous Close | $10.15 |
| Change ($) | 0.01 |
| Change (%) | 0.05% |
| Day's Open | 10.14 |
| Day's Range | 10.05 - 10.15 |
| Day's Volume | 642 |
| 52-Week Range | 4.35 - 12.01 |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) delivered earnings and revenue surprises of 0.00% and 9.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) delivered earnings and revenue surprises of 69.23% and 3.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) decreased 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 75.00% year over year to ($0.04), which beat th...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx Medical (NASDAQ:APYX) announces its next round of earnings this Wednesday, March 31. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).
Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q3 results.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
NEW YORK, July 30, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of Apyx Medic...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Ren...
PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stockholders. I...
NEW YORK, May 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASD...
Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor of Apyx Medical
Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q1 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2019 Results - Earnings Call Transcript
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for November 21st
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2019 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 13.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
About APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to ac... [Read more...]
| Industry Medical Devices | IPO Date Jan 1, 1987 |
| CEO Charles Goodwin | Employees 266 |
| Stock Exchange NASDAQ | Ticker Symbol APYX |
Financial Performance
In 2020, Apyx Medical's revenue was $27.71 million, a decrease of -1.86% compared to the previous year's $28.24 million. Losses were -$11.90 million, -39.63% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Apyx Medical stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 23.15% from the latest price.